These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 27214015)

  • 1. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations.
    Berntorp E; Ekman M; Gunnarsson M; Nilsson IM
    Haemophilia; 1996 Apr; 2(2):95-9. PubMed ID: 27214015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation.
    Salvagno GL; Astermark J; Ekman M; Franchini M; Guidi GC; Lippi G; Poli G; Berntorp E
    Haemophilia; 2007 Jan; 13(1):51-6. PubMed ID: 17212725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance?
    Berntorp E
    Haematologica; 2003 Jun; 88(6):EREP03. PubMed ID: 12826529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in inhibitor reactivity in acquired haemophilia A with different concentrates.
    Sukhu K; Keeling DM; Giangrande PL
    Clin Lab Haematol; 2000 Oct; 22(5):287-90. PubMed ID: 11122270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.
    Astermark J; Voorberg J; Lenk H; DiMichele D; Shapiro A; Tjönnfjord G; Berntorp E
    Haemophilia; 2003 Sep; 9(5):567-72. PubMed ID: 14511295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
    Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
    Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of proteases in AHF concentrates: effect on factor VIII:von Willebrand protein as assessed by high-pressure gel permeation chromatography.
    Orthner CL
    J Lab Clin Med; 1984 Nov; 104(5):816-28. PubMed ID: 6436416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
    Gringeri A; Musso R; Mazzucconi MG; Piseddu G; Schiavoni M; Pignoloni P; Mannucci PM;
    Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of substrate and diluent for factor VIII activity in highly purified factor VIII concentrate and patient plasma infused factor VIII concentrate].
    Takahashi I; Furuta M; Mizuno S; Takamatsu J; Kamiya T
    Rinsho Byori; 1993 Jul; 41(7):825-30. PubMed ID: 8361054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
    Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
    Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Von Willebrand factor multimers in virus-inactivated plasmas and F VIII concentrates.
    Budde U; Drewke E
    Beitr Infusionsther Transfusionsmed; 1994; 32():408-14. PubMed ID: 9422121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.
    Escolar G; Carretero M; Magallón M; Quintana M; Arnau C; Castillo R; Aznar-Salatti J
    Haematologica; 1998 Nov; 83(11):1009-14. PubMed ID: 9864923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of von Willebrand factor activity in factor VIII/von Willebrand factor concentrates with the automated von Willebrand factor: activity IL test.
    Mori F; Rossi P; Nardini I; Gambelli D; Farina C
    Blood Coagul Fibrinolysis; 2010 Apr; 21(3):221-8. PubMed ID: 20179578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inhibitor to factor VIII:C in a patient with possible combined haemophilia A and von Willebrand's disease.
    Taylor LD; Dean FL; Tiedemann K; Ekert H
    Thromb Haemost; 1986 Apr; 55(2):158-61. PubMed ID: 3087000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
    Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.